EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Inhalability and Bioactivity of Spray‐Dried versus Pressurized Gas eXpanded Liquid Technology‐Processed Yeast Beta‐Glucan Microparticles for Anti‐Fibrotic Therapies

Nate Dowdall iD, Safaa Naiel, Quan Zhou, Pareesa Ali, Tamana Rubina Yousof iD, Emily Wong, Ricardo Couto, Byron Yépez, Bernhard Seifried iD, Paul Moquin iD, Rod Rhem, Myrna Dolovich iD und 3 weitere

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202501952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Nate Dowdall und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, McMaster University, Hamilton, Ontario, L8S 4L8, Canada. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, beta-Glucans, Macrophages, Antifibrotic Agents. Die Arbeit nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: The Natural Sciences and Engineering Research Council of Canada, CIHR, Mitacs Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current anti‐fibrotic therapeutics for idiopathic pulmonary fibrosis (IPF) slow disease progression but are non‐curative and have systemic side effects, promoting interest in therapies that can repolarize macrophages away from their pro‐fibrotic phenotype. While yeast beta‐glucan (YBG) offers therapeutic potential in reprogramming macrophages toward an anti‐fibrotic phenotype, YBG processing must be optimized to promote inhalability while preserving its biological activity. Herein, the biological and inhalation performance of YBG processed via Pressurized Gas eXpanded liquids technology (PGX TEC ‐YBG) relative to conventionally spray‐dried YBG (SD‐YBG) is compared. The significantly smaller size and lower density of PGX TEC ‐YBG relative to SD‐YBG result in a smaller aerodynamic diameter (3–4 µm) and double the fine particle fraction in cascade impaction studies, variables correlated with improved inhalability and thus deposition in the distal regions of the lung. Correspondingly, PGX TEC ‐YBG shows an approximately double phagocytic index in vitro and enhanced suppression of CD206 expression and arginase‐1 activity, lower levels of macrophage stress, and comparable capacity for promoting pro‐inflammatory cytokine release in ex vivo murine precision cut lung slices relative to SD‐YBG. These findings highlight PGX TEC ‐YBG's utility as a promising inhalable therapeutic that can offer improved delivery to the disease site while maintaining strong biological anti‐fibrotic effects and reduced systemic toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary Fibrosisbeta-GlucansMacrophagesAntifibrotic AgentsSaccharomyces cerevisiaeAdministration, InhalationParticle SizeTHP-1 CellsLungPhagocytosisInflammation MediatorsHumansAnimalsMiceSpray DryingPressureRAW 264.7 CellsFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

fibrosisimmunomodulationinhalationmacrophagesyeast beta‐glucan

Substanzen

beta-GlucansInflammation MediatorsAntifibrotic Agents

Autor:innen und Institutionen

  • Department of Chemical Engineering, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.
  • Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, L8S 4L8, Canada.
  • Department of Medicine, Division of Nephrology, St. Joseph's Healthcare Hamilton, Hamilton Center for Kidney Research, McMaster University, Hamilton, ON, L8N 4A6, Canada.
  • Ceapro, Inc., 7824-51 Avenue NW, Edmonton, Alberta, T6E 6W2, Canada.
  • Firestone Research Aerosol Laboratory, St. Joseph's Healthcare and Faculty of Health Sciences, Department of Medicine, McMaster University, Hamilton, Ontario, L8N 4A6, Canada.

ORCID-Profile: Nate Dowdall, Tamana Rubina Yousof, Bernhard Seifried, Paul Moquin, Myrna Dolovich, Martin Rainer Kolb, Kjetil Ask, Todd Hoare

Förderung

  • The Natural Sciences and Engineering Research Council of Canada
  • CIHR
  • Mitacs Canada
  • Canadian Institutes of Health Research

Zitieren

APA

Dowdall, N., Naiel, S., Zhou, Q., Ali, P., Yousof, T. R., Wong, E., Couto, R., Yépez, B., Seifried, B., Moquin, P., Rhem, R., Dolovich, M., Kolb, M. R., Ask, K., & Hoare, T. (2025). Inhalability and Bioactivity of Spray‐Dried versus Pressurized Gas eXpanded Liquid Technology‐Processed Yeast Beta‐Glucan Microparticles for Anti‐Fibrotic Therapies. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202501952

Vancouver

Dowdall N, Naiel S, Zhou Q, Ali P, Yousof TR, Wong E, et al. Inhalability and Bioactivity of Spray‐Dried versus Pressurized Gas eXpanded Liquid Technology‐Processed Yeast Beta‐Glucan Microparticles for Anti‐Fibrotic Therapies. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202501952

BibTeX
@article{Dowdall2025,
  author = {Dowdall, Nate and Naiel, Safaa and Zhou, Quan and Ali, Pareesa and Yousof, Tamana Rubina and Wong, Emily and Couto, Ricardo and Yépez, Byron and Seifried, Bernhard and Moquin, Paul and Rhem, Rod and Dolovich, Myrna and Kolb, Martin Rainer and Ask, Kjetil and Hoare, Todd},
  title = {Inhalability and Bioactivity of Spray‐Dried versus Pressurized Gas eXpanded Liquid Technology‐Processed Yeast Beta‐Glucan Microparticles for Anti‐Fibrotic Therapies},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202501952}
}
Kostenlos starten →